Profile data is unavailable for this security.
About the company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.
- Revenue in USD (TTM)80.00k
- Net income in USD-17.61m
- Incorporated1996
- Employees12.00
- LocationCyclacel Pharmaceuticals Inc200 Connell Dr Ste 1500BERKELEY HEIGHTS 07922-2811United StatesUSA
- Phone+1 (908) 517-7330
- Fax+1 (866) 271-3466
- Websitehttps://cyclacel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Regen BioPharma Inc | 236.57k | -882.60k | 1.44m | 1.00 | -- | -- | -- | 6.10 | -0.2157 | -0.2157 | 0.0594 | -1.18 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
PaxMedica Inc | 0.00 | -17.66m | 1.50m | 6.00 | -- | -- | -- | -- | -7.54 | -7.54 | 0.00 | -0.2324 | 0.00 | -- | -- | 0.00 | -594.25 | -755.77 | -2,502.49 | -- | -- | -- | -- | -- | -- | -11,785.74 | -- | -- | -- | -- | -23.56 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 80.00k | -17.61m | 1.76m | 12.00 | -- | 1.61 | -- | 21.96 | -16.14 | -16.14 | 0.0423 | 0.5534 | 0.0065 | -- | 0.0547 | -- | -142.14 | -57.58 | -327.21 | -69.81 | -- | -- | -21,882.50 | -18,789.29 | -- | -100.52 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Aclarion Inc | 53.95k | -5.90m | 1.77m | 6.00 | -- | 0.8835 | -- | 32.90 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
Hi-Great Group Holding Co | 71.99k | -74.35k | 1.78m | -- | -- | -- | -- | 24.73 | -0.0007 | -0.0007 | 0.0007 | -0.0013 | 0.7149 | 0.627 | -- | -- | -73.83 | -- | -- | -- | 51.28 | -- | -103.28 | -- | 0.0099 | -20.74 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
Kiromic Biopharma Inc | 0.00 | -26.21m | 1.82m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
Bluejay Diagnostics Inc | 0.00 | -9.40m | 1.94m | 10.00 | -- | 0.035 | -- | -- | -44.53 | -44.53 | 0.00 | 3.34 | 0.00 | -- | -- | 0.00 | -97.27 | -- | -121.76 | -- | -- | -- | -- | -- | -- | -19.61 | 0.0185 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
Panbela Therapeutics Inc | 0.00 | -28.56m | 1.94m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -25.25m | 2.05m | 40.00 | -- | 0.1397 | -- | -- | -46.21 | -45.63 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -115.20 | -47.16 | -160.28 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Salarius Pharmaceuticals Inc | 0.00 | -6.46m | 2.06m | 2.00 | -- | 0.386 | -- | -- | -12.64 | -12.64 | 0.00 | 3.70 | 0.00 | -- | -- | 0.00 | -82.83 | -69.27 | -119.83 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.00 | -- | -- | -- | 60.32 | -- | -- | -- |
Dermata Therapeutics Inc | 0.00 | -9.82m | 2.07m | 8.00 | -- | 0.2862 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Point72 Asset Management LPas of 31 Mar 2024 | 15.33k | 1.05% |
Acadian Asset Management LLCas of 30 Jun 2024 | 14.29k | 0.98% |
UBS Securities LLCas of 31 Mar 2024 | 4.84k | 0.33% |
Tower Research Capital LLCas of 31 Mar 2024 | 4.19k | 0.29% |
McIlrath & Eck LLCas of 31 Mar 2024 | 832.00 | 0.06% |
Activest Wealth Management LLCas of 30 Jun 2024 | 133.00 | 0.01% |
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 126.00 | 0.01% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 80.00 | 0.01% |
Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 33.00 | 0.00% |
SignatureFD LLCas of 30 Jun 2024 | 20.00 | 0.00% |